

Discovery of a Novel Non-Narcotic Analgesic Derived from the CL-20 Explosive: Synthesis, Pharmacology, and Target Identification of Thiowurtzine, a Potent Inhibitor of the Opioid Receptors and the Ion Channels

Stephanie Agüero,¹ Simon Megy,¹ Valeria V. Eremina, Alexander I. Kalashnikov, Svetlana G. Krylova, Daria A. Kulagina,* Ksenia A. Lopatina, Mailys Fournier, Tatyana N. Povetyeva, Alexander B. Vorozhtsov, Sergey V. Sysolyatin, Vadim V. Zhdanov, and Raphael Terreux*



Cite This: *ACS Omega* 2021, 6, 15400–15411



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: The number of candidate molecules for new non-narcotic analgesics is extremely limited. Here, we report the identification of thiowurtzine, a new potent analgesic molecule with promising application in chronic pain treatment. We describe the chemical synthesis of this unique compound derived from the hexaazaisowurtzitane (CL-20) explosive molecule. Then, we use animal experiments to assess its analgesic activity *in vivo* upon chemical, thermal, and mechanical exposures, compared to the effect of several reference drugs. Finally, we investigate the potential receptors of thiowurtzine in order to better understand its complex mechanism of action. We use docking, molecular modeling, and molecular dynamics simulations to identify and characterize the potential targets of the drug and confirm the results of the animal experiments. Our findings finally indicate that thiowurtzine may have a complex mechanism of action by essentially targeting the mu opioid receptor, the TRPA1 ion channel, and the Ca_v voltage-gated calcium channel.



INTRODUCTION

Synthesis of candidate molecules for the design of non-narcotic analgesics to relieve severe and moderate pain is a trending topic in pharmaceuticals. Three types of treatments against pain of different etiologies are primarily used in out-patients and in-patients: (1) opioid and cannabinoid molecules with various analgesic activities, (2) nonsteroidal anti-inflammatory drugs (NSAIDs) acting as antalgic molecules, and (3) their various combinations in multimodal approaches for chronic pain, incorporating modalities such as physiotherapy, psychological therapy, patient education, and peripheral stimulation.^{1–5} An alternative to opiates for severe and moderate pain relief may reside in the use of non-narcotic analgesics acting on the central and peripheral nervous systems. However, the potential candidate molecules for non-narcotic analgesics are extremely limited in number. In this regard, one of the current successful approaches for the discovery of new molecules for biomedical research is the development of high-throughput methods of virtual screening for large databases of chemical compounds.^{6–8}

Here, we report the development of a new patented analgesic molecule,⁹ hereafter referred to as thiowurtzine, based on the hexaazaisowurtzitane (CL-20) molecule, a substance commonly known as a component of rocket fuel and explosives. Although several explosives such as nitroglycerin or potassium nitrate have

been used as drugs in medical history,^{10–13} the case of thiowurtzine is quite different, as it is directly derived from the CL-20 molecule but lacks all of the six nitro groups which confer its explosive properties to CL-20. As the six nitro groups are added only during the very last step of the chemical synthesis of CL-20,¹⁴ thiowurtzine can very well be considered more as a modified precursor rather than a revised explosive molecule.

Hexaazaisowurtzitane derivatives are caged polycyclic polynitrogen compounds and possess a framework structure determining their unique properties.^{15,16} Yet, numerous studies focused on the synthesis of new hexaazaisowurtzitane derivatives have until recently been primarily focused on their explosive and propelling properties for military purposes as promising components of solid rocket fuel and composite explosives.^{16,17}


Received: April 3, 2021

Accepted: May 20, 2021


Published: May 31, 2021



Scheme 1. Synthesis of Thiowurtzine (I)



Scheme 2. Optimized Procedure for Dibromothiophene Carboxylic Acid (IV)



Only in recent years has hexaazaisowurtzitane been investigated as a new pharmacophore for the development of original pharmaceutical substances. In this more biological context, preliminary studies investigating the analgesic activity of hexaazaisowurtzitane derivatives have recently been described.¹⁸ The aim of the project was to conduct conclusive preclinical studies of drugs based on the hexaazaisowurtzitane molecule for the treatment of the pain syndrome caused by different etiologies.

Thiowurtzine is the first chemical compound in the class of hexaazaisowurtzitane that presents a significant, experimentally validated bioactivity.^{15,19} After different patents of the molecule^{9,20} were published, we started to investigate its potential targets using computational techniques.

In this study, we report for the first time the synthesis of 4-(3,4-dibromothiophenecarbonyl)-2,6,8,12-tetraacetyl-2,4,6,8,10,12-hexaazatetracyclo[5,5,0,0^{3,11},0^{5,9}]dodecane (thiowurtzine, I), whose properties were predicted using the PASS software package.²¹ Then, we use animal experiments to assess its analgesic activity *in vivo* upon chemical, thermal, and mechanical exposures, compared to the effect of several reference molecules. Finally, we provide the first investigation on the potential receptors of thiowurtzine in order to better understand its mechanism of action. We use docking, molecular modeling, and molecular dynamics (MD) simulations to identify and characterize the potential targets of the drug and confirm the results of the animal experiments.

RESULTS AND DISCUSSION

Chemistry. A series of sequential reactions were used for the synthesis of thiowurtzine (I) as a final compound, as illustrated in Scheme 1.

For the synthesis of compound IV, we optimized the procedure involving exhaustive bromination of thiophene, reduction with zinc dust to dibromothiophene, alkylation in the presence of titanium tetrachloride, and final oxidation of aldehyde to the desired dibromothiophene carboxylic acid IV.

The yield of IV on a thiophene (VII) basis was 37%. In case compound VIII was used, the yield of IV was 73%. These

reactions are illustrated in Scheme 2. As pictured in Scheme 1, acylating agent II was obtained in a quantitative yield by treating 3,4-dibromothiophene carboxylic acid IV by boiling thionyl chloride for 1 h.

Synthetic methods for tetraacetyl hexaazaisowurtzitane (III) are commonly known and industrially employed.^{22–24} A cascade condensation of benzylamine with glyoxal furnished hexabenzyl hexaazaisowurtzitane (V). Two-stage hydrogenation of V over the Pd catalyst produced VI (Scheme 1).

The acylation reaction between starting III and chloroanhydride II was performed in boiling acetonitrile. The use of other organic solvents diminished the yield of product I. To lower the quantity of impurities, diamine III in acetonitrile was treated with acylating agent II, with compound I precipitating from the reaction mixture and not undergoing further reactions (Scheme 1).

No excess acylating agent II was required to complete the reaction. When II was used in excess from 0 to 65%, the yield of I ranged from 79 to 82%.

The structure of the obtained compound I was verified by a complex approach via physicochemical methods, including ¹H and ¹³C NMR spectra (as illustrated in the Supporting Information).

Biological Evaluation. The predicted analgesic activity of the resulting compound I was confirmed on animals using the reference drugs tramadol, ketorolac, and diclofenac.

Two experimental series with chemical pain stimulation of the peritoneum showed a pronounced antinociceptive effect of thiowurtzine upon a single (100 mg/kg) and subchronic intragastric administration to mice in doses of 50 and 100 mg/kg (Table 1). After a single administration (100 mg/kg), thiowurtzine significantly relieved acute visceral pain by 56.4% and prolonged the pain response time ($p < 0.05$) in reference to the negative control and appeared to be equivalent to the reference drug, tramadol, which exhibits a 62.2% pain response inhibition (Table 1, series I). It should be noted that in the second series of experiments, after a 4-day compound administration in doses of 50 and 100 mg/kg, thiowurtzine reduced the number of writhings by 56.9% ($p < 0.01$) and 47.1%

Table 1. Antinociceptive Effect of Thiwurtzine in the Acetic Acid Writhing Test ($X \pm m$)^a

group	number of writhings within 20 min	writhing latency, s	pain response inhibition, %
Series I: Inbred Male CBA Mice. Single Administration of Thiwurtzine and Tramadol			
(1) negative control—vehicle (<i>n</i> = 9)	24.1 ± 3.4	160.9 ± 86.4	0
(3) tramadol, 20 mg/kg (<i>n</i> = 9)	9.1 ± 2.0, ** ⁽¹⁻³⁾	444.8 ± 42.8, ** ⁽¹⁻³⁾	62.2
(5) thiwurtzine, 100 mg/kg (<i>n</i> = 6)	10.5 ± 3.0, * ⁽¹⁻⁵⁾	382.5 ± 120.4, * ⁽¹⁻⁵⁾	56.4
Series II: Outbred Male Mice, Stock CD1. Drug Administration for 4 days			
(1) negative control—vehicle (<i>n</i> = 10)	27.4 ± 3.1	276 ± 15	
(2) diclofenac, 10 mg/kg (<i>n</i> = 10)	18.2 ± 1.2, ** ⁽¹⁻²⁾	270 ± 10	33.6
(3) thiwurtzine, 50 mg/kg (<i>n</i> = 10)	11.8 ± 2.9, ** ⁽¹⁻³⁾ , *(2-3)	270 ± 10	56.9
(4) thiwurtzine, 100 mg/kg (<i>n</i> = 10)	14.5 ± 3.0, ** ⁽¹⁻⁴⁾	273 ± 16	47.1

^a**p* < 0.05, ***p* < 0.01 compared to the negative control and the reference group (Mann–Whitney *U* test).

(*p* < 0.01) in comparison with the control, respectively (Table 1, series II). Thiwurtzine (50 mg/kg) exceeded the activity of reference drug diclofenac.

The most pronounced analgesic effect of thiwurtzine was revealed in the central analgesia model, which is controlled by the cortical and subcortical structures of the brain. In the hot plate test, subchronic intragastric administration of thiwurtzine in a dose of 100 mg/kg caused a maximum increase in the pain response latency of 77.9%—by 1.8 times (*p* < 0.01)—relative to the control (Table 2, series I and II). Thiwurtzine (100 mg/kg) exceeded the activity of the reference drug diclofenac, where pain response inhibition proved to be 11.3%.

Thiwurtzine showed a roughly constant increase in the nociceptive threshold throughout the study, which was noted to be significant in the 100 mg/kg group (Table 3). After a single

Table 2. Analgesic Activity of Thiwurtzine in the Hot Plate Test in Outbred Male Stock CD Rats ($X \pm m$)^a

group	pain response latency, s	pain response inhibition, %
Series I: Drug Administration for 4 days		
(1) negative control—vehicle (<i>n</i> = 8)	9.8 ± 1.0	
(2) diclofenac, 5 mg/kg (<i>n</i> = 9)	10.9 ± 1.5	11.3
(3) thiwurtzine, 25 mg/kg (<i>n</i> = 9)	10.4 ± 1.3	6.1
(4) thiwurtzine, 50 mg/kg (<i>n</i> = 8)	12.1 ± 1.6	23.5
Series II: Drug Administration for 4 days		
(1) negative control—vehicle (<i>n</i> = 10)	11.3 ± 1.0	
(2) thiwurtzine, 100 mg/kg (<i>n</i> = 10)	20.1 ± 2.3, ** ⁽¹⁻²⁾	77.9
(3) thiwurtzine, 200 mg/kg (<i>n</i> = 10)	14.9 ± 2.1, *(2-3)	31.9
(4) thiwurtzine, 300 mg/kg (<i>n</i> = 10)	13.2 ± 2.7	16.8

^a**p* < 0.05, ***p* < 0.01 compared to the negative control and the reference group (Mann–Whitney *U* test).

administration (100 mg/kg), thiwurtzine significantly increased the supporting pressure in the left hind paw pad by 2.1 times (1 h, *p* < 0.01) and 1.6 times (4 h, *p* < 0.01), relative to the negative control.

Interestingly, the Randall–Selitto test performed on the right paw (100 mg/kg) with formalin edema also revealed a significant increase in the nociceptive threshold. In this case, increased supporting pressure was evidenced by 4.4 times (1 h, *p* < 0.01) and 2.0 times (4 h, *p* < 0.01) compared to that of the negative control.

The assessed effect of thiwurtzine (100 mg/kg) on thresholds of response to mechanical pressure stimulation appeared to be comparable with tramadol but exceeded the activity of the reference drug ketorolac.

The preclinical study demonstrated that chronic administration of thiwurtzine (abstinence syndrome) did not evoke drug abuse. There was no impact on respiration and the central nervous system, indicating that thiwurtzine is not a morphine-like action compound and does not cause ulcerogenic damage to the gastrointestinal mucosa of the test animals.

Target Identification. Previous studies investigating the action of naloxone and naloxone methiodide demonstrated that naloxone has a higher affinity than naloxone methiodide for the mu, kappa, and delta opioid receptors in the brain of the mouse.²⁵ Therefore, naloxone targets the brain tissue, whereas naloxone methiodide, which has limited access to the brain, targets more specifically the peripheral opioid receptors.

Interestingly, injection of nonselective opioid receptor antagonist naloxone was shown to weaken the analgesia caused by a single thiwurtzine administration in a dose of 100 mg/kg,¹⁸ suggesting an action on the mu, kappa, and delta opioid receptors in the central opioid system of the mouse.

On the contrary, naloxone methiodide did not abolish analgesia, suggesting that thiwurtzine has no affinity for the peripheral opioid receptors.

These results are consistent with the central opioid system being involved in the mediation of the analgesic effect of thiwurtzine. For this reason, different opioid receptors (mu, kappa, and delta) and the opioid-like receptor 1 (ORL1) were investigated as potential targets using computational methods.

However, the antinociceptive effect of thiwurtzine was not completely abolished by naloxone, which suggests a complex mechanism of action of the compound under study. In this regard, the opioid analgesia pathway seems to be only one component of the mechanism of action of thiwurtzine; and consequently, there may be other targeted receptors.

Another target of choice for the action of thiwurtzine may be the transient receptor potential (TRP) ion channel family, whose discovery was an important step in exploring the nature of pain sensation at the molecular level. These channels are tetramers assembled from subunits with six membrane-spanning domains and are permeable to monovalent cations and calcium. This family of receptors is currently considered as the pharmacologically most important biotargets of the human nervous system for analgesia.

Recent results proved that thiwurtzine, when administered in a preventive single per os dose of 100 and 200 mg/kg, was found to effectively block nociceptive reactions normally caused by the activation of the TRPA1 and TRPV1 ion channels. That being said, the thiwurtzine analgesic activity turned out to be comparable and/or superior to that of ketorolac and diclofenac, depending on the model situation. Besides, thiwurtzine (200 mg/kg per os) was found to be equivalent to diclofenac sodium

Table 3. Analgesic Activity of Thiwurtzine in the Randall–Selitto Test in Outbred Male Stock CD1 Mice ($X \pm m$)^a

group	supporting pressure in the left hind paw pad, g/condition		supporting pressure in the right hind paw pad with formalin edema, g/condition	
	1 h after drug administration	4 h after drug administration	1 h after drug administration, 1–5 min after injection of formalin	1 h after drug administration, 40–50 min after injection of formalin
(1) negative control—vehicle ($n = 10$)	294.9 ± 48.4	373.2 ± 70.9	141.1 ± 23.7	305.2 ± 72.6
(2) tramadol, 10 mg/kg ($n = 9$)	645.2 ± 40.8, ** ⁽¹⁻²⁾	606.7 ± 53.9, ** ⁽¹⁻²⁾	318.9 ± 84.1, * ⁽¹⁻²⁾	518.0 ± 85.0, * ⁽¹⁻²⁾
(3) ketorolac, 6 mg/kg ($n = 8$)	521.2 ± 107.9, ** ⁽¹⁻³⁾	449.7 ± 90.4	491.4 ± 88.2, * ⁽¹⁻³⁾	396.6 ± 94.1
(4) thiwurtzine, 100 mg/kg ($n = 9$)	631.5 ± 43.9, ** ⁽¹⁻⁴⁾	612.9 ± 43.8, ** ⁽¹⁻⁴⁾	620.8 ± 60.0, ** ⁽¹⁻⁴⁾	611.3 ± 58.8, ** ⁽¹⁻⁴⁾
(5) thiwurtzine, 200 mg/kg ($n = 9$)	586.1 ± 68.6, ** ⁽¹⁻⁵⁾	455.8 ± 81.7	419.7 ± 94.2, * ⁽¹⁻⁵⁾	366.3 ± 88.3

^a* $p < 0.05$, ** $p < 0.01$ compared to the negative control and the reference group (Mann–Whitney U test).

Table 4. Docking Scores of Thiwurtzine and Control Drugs against the Mu, Kappa, Delta, and ORL1 Opioid Receptors, the TRPA1 and TRPV1 Ion Channels, and the Ca_v 1.2 Calcium Channel^a

drug	GOLD score with the mu receptor	GOLD score with the kappa receptor	GOLD score with the delta receptor	GOLD score with the ORL1 receptor	GOLD score with the TRPA1 receptor	GOLD score with the TRPV1 receptor	GOLD score with the Ca _v 1.2 receptor
tramadol 1S-2S	19,546	27,003	21,797	20,520	24,965	21,236	24,499
tramadol 1R-2R	19,188	28,349	20,435	19,272	23,058	21,497	23,597
ketorolac	19,529	26,150	23,640	19,467	23,712	19,717	22,065
diclofenac	20,823	31,603	24,274	17,567	22,406	20,449	24,154
thiwurtzine	8,465	2,730	6,407	2,153	14,831	8,414	15,562

^aThe scores of the GOLD³⁸ docking software using the Chemscore^{40,41} rescore function are displayed.

(10 mg/kg per os) and superior in anti-inflammatory expressiveness to ketorolac (6 mg/kg per os) in the formalin test. The test results suggest that the pronounced antinociceptive action of our innovative compound in the capsaicin and formalin tests is governed by the interaction with the TRPV1 and TRPA receptors. Moreover, all the data previously obtained are consistent with the analgesic action of thiwurtzine, triggering the activity modulation of the TRP ion channels. In this regard, the TRPA1 and TRPV1 ion channels were also investigated as potential targets using docking techniques.

It should also be noted that the preventive single intragastric gavage administration of thiwurtzine at a dose of 100 mg/kg led to a statistically significant decrease in the number of myoclonic seizures relative to the similar value of the carbamazepine group. This also resulted in a comparative increase in the life expectancy of animals while exceeding the main indicator of the effectiveness of an anticonvulsant action—an increase in the number of surviving animals (41.7% relative to 33.3% of the carbamazepine group).²⁰

The mechanism of the anticonvulsant action can probably be attributed to both allosteric interactions with components of the γ -aminobutyric acid type A receptor complex and the effect on Ca²⁺-dependent K⁺ currents.

Finally, in order to identify new potential targets for the action of thiwurtzine, we screened the DrugBank database,²⁶ looking for structurally similar drugs and their well-known receptors. Interestingly, we identified several drugs classified as calcium antagonists and acting as calcium channel blockers (namely, pranidipine, nifedipine, and especially lacidipine, which exhibited the highest score of 86% for structural similarity with thiwurtzine). Lacidipine, like other dihydropyridines, targets another family of calcium channels, namely, the voltage-dependent calcium channels, and has a selective activity on the

Ca_v 1.2 channel. Dihydropyridines have a high affinity for these receptors ranging from 0.1 to 50 nM, and they specifically interact with their α_{1c} subunit.²⁷ This led us to investigate this class of voltage-gated calcium channels as potential targets for thiwurtzine. Indeed, calcium channel blockers have the ability to inhibit voltage-gated calcium channels, and thus, reduce the release of neurotransmitters at the presynaptic level, which may lead to pain reduction. As a consequence, voltage-gated calcium channels have been described as targets of choice for potential analgesics in the previous years,^{28–32} especially when used concomitantly with opioids in attenuation of clinical pain.^{33–35} In this particular case, calcium channel blockers have been shown to increase morphine analgesia.^{36,37}

As a result, we used the Genetic Optimization for Ligand Docking (GOLD) software³⁸ to perform docking experiments for the thiwurtzine molecule on the mu, kappa, delta, and ORL1 opioid receptors, the TRPA1 and TRPV1 ion channels, and voltage-dependent calcium channel Ca_v 1.2.

The mu, kappa, delta, and ORL1 opioid receptors were constructed using the corresponding UniProtKB human sequences and the Iterative Threading ASSEMBLY Refinement (I-TASSER) software from the Zhang Lab.³⁹ The models were then checked, charged, and minimized with the Molecular Operating Environment (MOE) software using the Amber 14:ETH force field.

The structure of the TRPA1 human receptor was directly extracted from the PDB file 6PQO, and the structure of the human TRPV1 ion channel was calculated as a homology model using the rat structure of the PDB file 3J5Q as a template and the Uniprot human sequence Q8NER1.

For human calcium channel Ca_v 1.2, we built a homology model using UniProtKB sequence Q13936 (isoform 1) of human voltage-gated calcium channel subunit α_{1c} Ca_v 1.2 and




Figure 1. Molecular representation of the best docking pose of the thioiwurtzine molecule interacting with the calculated model of the human mu opioid receptor. Thioiwurtzine is displayed as sticks, and the mu receptor is displayed as red ribbons. The water molecules are visible, as well as the molecular surface of the cavity surrounding the thioiwurtzine molecule. The side chains of the residues interacting with thioiwurtzine are labeled and displayed as sticks.




Figure 2. Molecular representation of the best docking pose of the thioiwurtzine molecule interacting with the human TRPA1 ion channel from the PDB file 6PQO. Thioiwurtzine is displayed as sticks, and the TRPA1 receptor is displayed as red ribbons. The molecular surface of the cavity surrounding the thioiwurtzine molecule is displayed with a gray surface. The side chains of the residues interacting with thioiwurtzine are labeled and displayed as sticks.

the PDB structure 6JPS of the rabbit Ca_v 1.1 calcium channel interacting with the dihydropyridine compound nifedipine. As the calcium channel was an unexpected target, we thoroughly checked the structure as follows: the RMSD calculated between the final model and the template was 0.738 Å. The root-mean-square deviation (RMSD) between the binding sites (residues with atoms within a sphere of 4.5 Å around the nifedipine ligand) of 6JPS and the homology model was 0.32 Å, which indicates that the two binding sites are extremely similar. For supplemental validation, the Ramachandran diagram of the model was also checked with 93% of residues in the most favorable regions, 6% in the allowed regions, and only a few outlier residues. The homology model was further evaluated by docking nine ligands extracted from BindingDB (<http://bindingdb.org>). The docking scores were in very good agreement with the experimentally measured inhibitor constants

(K_i) for each of the nine ligands, thus validating the robustness of our model.

Docking of Thioiwurtzine. The docking of thioiwurtzine into the models of the seven receptors (mu, kappa, delta, ORL1, TRPA1, TRPV1, and Ca_v 1.2) was performed using the GOLD software. We used control drugs (tramadol, ketorolac, and diclofenac) as references. As tramadol is commercially available as a racemic mix (1R-2R and 1S-2S), we separately tested each of the two enantiomers and reported their respective scores. All the results are summarized in Table 4.

Interestingly, the docking scores of thioiwurtzine are lower than those of the reference drugs for all the investigated receptors. However, these scores are high enough to unequivocally demonstrate an effective binding of thioiwurtzine, especially with the mu and delta opioid receptors, the TRPA1 and TRPV1 ion channels, and the Ca_v calcium channel, which




Figure 3. Molecular representation of the last frame of the 200 ns molecular dynamic simulation of thioiwurtzine in complex with the model of the mu opioid receptor. Thioiwurtzine is displayed as thick sticks, the mu receptor as gray ribbons, and the lipids as cyan sticks. The trajectory of the thioiwurtzine mass center throughout the entire simulation is displayed as yellow lines. The side chains of the residues interacting with thioiwurtzine are displayed as sticks, and their name and number are indicated on the structure.




Figure 4. Molecular representation of the last frame of the 200 ns molecular dynamic simulation of thioiwurtzine in complex with the model of the Ca_v receptor. Thioiwurtzine is displayed as thick sticks, the Ca_v calcium channel as lime ribbons, and the lipids as cyan sticks. The trajectory of the thioiwurtzine mass center throughout the entire simulation is displayed as yellow lines. The side chains of the residues interacting with thioiwurtzine are displayed as sticks, and their name and number are indicated on the structure.

exhibits the highest docking score with thioiwurtzine in our study.

For the mu and delta receptors, the scores are about 2.5 to 4 times lower than those of tramadol, ketorolac, or diclofenac. However, the animal experiments proved that the doses of thioiwurtzine needed to be typically five times higher than those of tramadol (20 mg/kg vs 100 mg/kg) and diclofenac (10 mg/kg vs 50 mg/kg) to produce similar effects with the acetic acid writhing test (Table 1). The same ratio was also observed for the hot plate test (diclofenac 5 mg/kg and thioiwurtzine 25 mg/kg, Table 2) to produce similar results. Apart from the typical bioavailability issues, the animal experiments are thus in very good agreement with our docking results. The best docking pose for thioiwurtzine in complex with the model of the mu opioid receptor is displayed in Figure 1.

For the TRPA1 ion channel, the results with thioiwurtzine are much better than for any of the opioid receptors, with a docking score almost twice as high as the one obtained by the mu receptor; and all the reference drugs exhibit similar scores. Despite being about 35% lower than those of the different reference drugs, the docking score of thioiwurtzine, in this case, demonstrates a high affinity and a strong binding, as illustrated in Figure 2, which displays the best docking pose for thioiwurtzine in complex with the 6PQO PDB structure of the human TRPA1 ion channel.

For the TRPV1 receptor, the results are very similar to those obtained by the mu opioid receptor, with a very close docking score, and similar scores are exhibited by the reference drugs as well. In this regard, TRPV1 appears to be a target for thioiwurtzine about as good as the mu opioid receptor but significantly less valuable than TRPA1.

For the Ca_v receptor, the docking score of thioiwurtzine is better than for any of the other investigated receptors (Table 4), and it is close to those of the other reference drugs (albeit being about 30% lower). Consequently, thioiwurtzine appears to be a significantly better ligand for the Ca_v receptor than for any of the investigated opioid receptors and even slightly better than for the TRPA1 ion channel.

All these results are consistent with a complex mechanism of action, which could target at the same time the opioid receptors, the TRP channels, and the voltage-gated calcium channels.

Molecular Dynamics. In order to validate whether our hypothesis of thioiwurtzine binding to the mu opioid receptor and the Ca_v 1.2 calcium channel was stable over time, MD experiments were carried out for the mu receptor and the Ca_v 1.2 calcium channel in the presence of thioiwurtzine. We used the best docking pose of thioiwurtzine with the model of the mu receptor and the Ca_v 1.2 calcium channel as starting points. A lipid bilayer surrounding the receptors was generated with the MOE lipid generator for each protein. Water molecules were added, as well as Na^+ and Cl^- ions, in order to simulate a 0.1 M ionic force, and the pH was set at 7.4. Standard Amber 14:EHT parameters were used for MD. A quick minimization was performed prior to the start of the MD simulations. After a preliminary equilibration phase, 200 ns molecular simulations were performed. A frame was saved every 200 ps, leading to a total of 1000 frames. The last frame of each simulation is displayed in Figures 3 and 4 for the mu receptor and the Ca_v 1.2 calcium channel, respectively.

The molecular complex formed by thioiwurtzine with either the mu receptor or the Ca_v calcium channel model appeared to be extremely stable over time. The calculated RMSD for each of the receptors stayed quite stable along the simulations (as indicated in the Section S10). Moreover, for each receptor, thioiwurtzine stayed within the interaction site during the 200 ns simulation, with only limited relative motions around its initial position at the beginning of the simulation. The RMSDs calculated for thioiwurtzine in regard to each receptor are low and extremely stable over the simulation time (see the Section S10). The entire trajectory of the thioiwurtzine mass center during the complete simulation is displayed as yellow sticks in Figures 3 and 4 and indicates great stability of the complexes over time. These results are in excellent agreement with the good docking scores previously obtained with the GOLD software for the thioiwurtzine interaction with each of the receptors (Table 4).

CONCLUSIONS

In summary, we provided the chemical synthesis, biological evaluation, and *in silico* target identification of a potent new hexaazaisowurtzitane-based analgesic, referred to here as thioiwurtzine. This nonaddictive analgesic does not exhibit any of the typical adverse effects of NSAIDs and may very well lead to new compounds of the same class with practical applications.

It is worth noting that the devised original method for the synthesis of 3,4-dibromothiophene carboxylic acid holds promise for further use, as it provides quite a high yield under mild synthesis conditions.

The experimental evidence (behavioral tests with thermal and chemical stimuli and mechanical compression) demonstrates an analgesic effect of thioiwurtzine through its inhibitory action on the peripheral and central mechanisms of development and maintenance of pain syndrome. These findings highlight a

promising potential of the new compound as an analgesic against pain syndromes of different etiologies.

The software-based evaluation of thioiwurtzine, which was validated by the animal studies, gave some interesting perspectives about the potential molecular receptors of thioiwurtzine. We highlighted the role of the opioid receptors as primary targets, which confirmed the results of the experiments using thioiwurtzine in conjunction with naloxone. However, the antinociceptive effect of thioiwurtzine was not completely abolished by naloxone, which suggests that the opioid analgesia pathway may not be the only component of the mechanism of action of thioiwurtzine; consequently, there may be other targeted receptors as well.

Then, we investigated the TRP class of ion channels as targets for the thioiwurtzine molecule. The docking experiments with the TRPA1 and TRPV1 receptors allowed us to highlight the strong binding capabilities of this family of ion channels, especially for TRPA1, which exhibited an excellent docking score and thus proved to be an extremely valuable target for thioiwurtzine.

We also used molecular comparisons with other drugs, associated with molecular modeling and MD simulations, which allowed us to also consider voltage-gated calcium channels as potential targets. Interestingly, the possibility that calcium channel blockers might induce analgesia by reducing the release of neurotransmitters and thus increasing morphine analgesia has been investigated and confirmed in several studies.^{33–37} These results are consistent with thioiwurtzine having a primary action on the central opioid system and suggest that this primary action may very well be potentiated by a secondary action on the voltage-gated calcium channels as well. These results were confirmed by the docking scores of thioiwurtzine against the opioid and the calcium receptors. These findings might provide a solid basis for the explanation of the complicated mechanism of action of thioiwurtzine.

Our docking results also provide a molecular explanation of the non-narcotic properties of thioiwurtzine. As we proved that ion channels such as the TRP receptors and the Ca_v calcium channels are much better targets for thioiwurtzine than any of the opioid receptors, this might partly explain why thioiwurtzine does not have a morphine-like action and subsequently does not exhibit typical adverse effects of NSAIDs, as demonstrated by the animal studies.

New rational design studies involving further chemical modifications of hexaazaisowurtzitane derivatives are currently under way and might lead to the discovery of a whole new class of biologically active molecules of interest.

EXPERIMENTAL SECTION

General Methods. High-performance liquid chromatography (HPLC) was performed on an Agilent Technologies 1260 Infinity instrument with a 2.1×15 mm precolumn, Zorbax SB-18 sorbent, and $3 \mu\text{m}$ fractions; a 3.0×150 mm column, Zorbax SB-18 sorbent, and $3.5 \mu\text{m}$ fractions using gradient elution. Eluent A: 0.2% orthophosphoric acid solution and eluent B: acetonitrile. ^1H and ^{13}C NMR spectra were recorded on a Bruker AM-400 spectrometer operating at 400.13 MHz for ^1H and at 100.61 MHz for ^{13}C ; $\text{DMSO}-d_6$ was used as solvent. IR spectra were recorded on an Infracum FT-801 spectrophotometer in KBr pellets (1 mg substance in 200 mg potassium bromide) in the range of 4000 to 400 cm^{-1} . The melting point was measured on a Stuart SMP 30 melting point apparatus.

Synthesis of 2,4,6,8,10,12-Hexabenzyl-2,4,6,8,10,12-hexaazatetra-cyclo[5,5,0,0^{3,11},0^{5,9}]dodecane (V). Into a stirred flask were put benzylamine (170 mL, 1.56 mol), distilled water (130 mL), acetonitrile (1430 mL), and 98% formic acid (5.4 mL). Then, 40% aqueous glyoxal (94.25 g, 0.65 mol) was added portionwise for 1 h at a temperature not above 20 °C. The reaction mixture was maintained at room temperature for 17 h. The resultant crystalline product was collected by filtration and washed in situ with cold acetonitrile. Yield: 121 g (76% on a benzylamine basis). mp: 145–150 °C.

For deresination, the resultant crude product was stirred in acetonitrile (240–250 mL) at 50 °C for 15–20 min, cooled to room temperature, filtered, and then washed with acetonitrile to furnish 115–118 g of the product (mp: 150–153 °C) after drying. Calcd for C₄₈H₄₈N₆ (%): 81.32; H, 6.82; N, 11.85; found (%): C, 82.13; H, 6.79; N, 11.09. IR (ν/cm^{-1}): 3082, 3061, 3023, 2923, 2857, 2823, 1493, 1452, 1351, 1323, 1302, 1244, 1140, 1072, 987, 898, 835, 733, 699, 625. ¹H NMR (DMSO-*d*₆, δ , ppm): 3.48 (s, 2H, CH), 4.01 (s, 4H, CH₂), 4.04 (s, 4H, CH₂), 4.15 (s, 4H, CH), 7.14–7.26 (m, 30H, CHap).

Synthesis of 4,10-Dibenzyl-2,6,8,12-tetraacetyl-2,4,6,8,10,12-hexaazatetracyclo[5,5,0,0^{3,11},0^{5,9}]dodecane (VI). Into a 300 mL autoclave equipped with an electromagnetic stirrer and a hydrogen gas delivery system were loaded hexabenzylhexaazaisowurtzitane (10 g), bromobenzene (0.18–0.20 mL), a catalyst, and DMF (40 mL). Lastly, acetic anhydride (15 mL) was added, and the autoclave was closed. The autoclave was purged with hydrogen three times. Hydrogen was then supplied under 5–6 kgf/cm², stirring was turned on (550–600 rpm), and the autoclave was heated to 50–55 °C. The hydrogen absorption was controlled against the autoclave pressure drop. If the autoclave pressure went down below 2.5–2 kgf/cm², hydrogen was again fed at 5–6 kgf/cm².

After the process was complete (an autoclave pressure drop of 0.1–0.2 kgf/cm² within 1 h), the heating was turned off, cold water was poured into the bath, and the reactor was cooled to 20–25 °C.

Hydrogen depressurization was then performed, and the product suspension with the catalyst was filtered. The mixture of dibenzyltetraacetylhexaazaisowurtzitane (DBTA) and catalyst was washed with ethanol (3 × 10 mL), squeezed, and air-dried to furnish DBTA not allowing for the catalyst weight. Yield: 5.8–6 g (80–83%). Calcd for C₂₈H₃₂N₆O₄ (%): C, 65.10; H, 6.24; N, 16.27; O, 12.39; found (%): C, 64.79; H, 6.18; N, 16.25. IR (ν/cm^{-1}): 3083, 3044, 3022, 3005, 2876, 2829, 1687, 1650, 1455, 1412, 1358, 1319, 1300, 1239, 1147, 1068, 985, 893, 834, 730, 687, 627. ¹H NMR (DMSO-*d*₆, δ , ppm): 1.85–1.95 (m, 12H, CH₃), 4.09 (s, 4H, CH₂), 5.71 (br s, 4H, CH), 6.51 (br s, 4H, CH), 7.37–7.49 (m, 10H, CHap).

Synthesis of 2,6,8,12-Tetraacetyl-2,4,6,8,10,12-hexaazatetracyclo[5,5,0,0^{3,11},0^{5,9}]dodecane (III). Into an autoclave were loaded DBTA (25 g), 5% Pd/C (5 g), and 50% acetic acid (150 mL). The autoclave was closed and purged three times with nitrogen and two times with hydrogen. Hydrogen was then fed at 5 kgf/cm² and stirring was turned on. The reaction was carried out at 70–75 °C for 3 h. The catalyst was then filtered, and the reaction mixture was evaporated in a rotary evaporator until it was viscous. To the evaporated mixture was added alcohol (150–200 mL), and the whole mixture was stirred for 15–20 min. The crystalline product was collected by filtration and air-dried to give tetraacetylhexaazaisowurtzitane (TA). Yield: 15 g (92%), purity 98% (as per HPLC). mp: 360 °C (decomposition). Calcd for C₁₄H₂₀N₆O₈ (%): C, 49.99; H, 5.99;

N, 24.99; O, 19.03; found (%): C, 50.16; H, 6.04; N, 24.72. IR (ν/cm^{-1}): 3369, 3329, 3047, 3019, 2931, 1659, 1402, 1359, 1293, 1255, 1140, 1111, 1019, 974, 909, 801, 710, 609, 509. ¹H NMR (DMSO-*d*₆, δ , ppm): 1.94–2.07 (m, 12H, CH₃CO), 4.59–4.99 (m, 2H, NH), 5.29 (br s, 2H, CH), 5.99–6.23 (m, 4H, CH).

Synthesis of 3,4-Dibromothiophene Carboxylic Acid (IV). Into a round-bottom flask, thiophene (48 mL, 0.6 mol), chloroform (24 mL), and bromine (128 mL, 2.4 mol) were slowly added dropwise. The dosing time was 4 h. At the beginning of dosing, the solution was observed to be decolorized and hydrogen bromide evolved vigorously. Hydrogen bromide was entrapped and absorbed with 20% NaOH solution. After dosing was completed, the reaction mixture was cooled on an ice bath and held for 12 h.

Upon completion of holding, to the reaction mixture was added chloroform (20 mL), the whole mixture was heated on a silicone bath at 85 °C, and 15% KOH solution in ethanol was added. The mixture was refluxed for 3 h with vigorous stirring, cooled down, and then poured out onto ice (400 g). After holding for 1 h, the product was filtered, washed with water, and air-dried.

To a 1 L flask fitted with a distiller was added zinc powder (180.6 g, 2.76 mol) in water (240 mL), and then, glacial acetic acid (180 mL, 5.2 mol) was added. The reaction mixture was heated to boil, and the crude product was added in a few portions. The distilled organic fraction was washed with water and then dried over MgSO₄ to yield 3,4-dibromothiophene as a colorless liquid. Yield: 74.07 g (51%).

To a mixture of the resultant 3,4-dibromothiophene (0.024 mol) and dichloromethyl methyl ether (2.98 g, 2.35 mL, 0.026 mol) in dry dichloromethane (15 mL) was added TiCl₄ (7.59 g, 4.39 mL, 0.04 mol) with stirring at –12 °C for 40–50 min. The reaction mixture was stirred for 1 h, and water (30 mL) was added drop by drop within 15 min. After 30 min, the layers were separated, and the water layer was extracted with dichloromethane (3 × 30 mL). The combined extract was dried over MgSO₄ and evaporated. The product was recrystallized from heptane, dried, and used in the subsequent stage.

The resultant 3,4-dibromo-2-thiophene-aldehyde (47.1 g, 0.174 mol) was dissolved in acetone (550 mL). A potassium permanganate (37.8 g) solution in distilled water (720 mL) was prepared separately by heating.

To the aldehyde acetone solution was added potassium permanganate in portions of 15–20 mL at not above 20 °C. The whole solution was held for 3–5 min after adding each portion. The dosing was stopped after the solution turned a stable pink color. The resultant suspension was decolorized by adding 10% sodium sulfite solution. The reaction mixture was filtered off of MnO₂ and washed with water.

The filtrate was evaporated by half and acidified with HCl until the pH value was less than 2. The product was collected by filtration, washed with water and then recrystallized from dichloroethane to yield 3,4-dibromothiophene carboxylic acid. Yield: 42.29 g (85%). mp: 205–207 °C. Calcd for C₅H₂Br₂O₂S (%): C, 21.00; H, 0.70; Br, 55.89; O, 11.19; S, 11.21; found (%): C, 21.09; H, 0.69; S, 11.24. IR (ν/cm^{-1}): 3102, 3098, 1663, 1478, 1389, 1321, 1123, 920, 857, 784, 685. ¹H NMR (DMSO-*d*₆, δ , ppm): 7.44 (c, 1H, CH), 10.93 (br s, 1H, OH).

Synthesis of 3,4-Dibromothiophenecarbonyl chloride (II). 3,4-Dibromothiophene carboxylic acid (10 g, 0.035 mol) was added to thionyl chloride (50 mL) and heated to the boiling point of thionyl chloride. The mixture was maintained at the

same temperature for 1 h and then cooled down and evaporated in a rotary evaporator. Yield: 9.2 g (86%). mp was not measured because the product was immediately used in further reaction.

Synthesis of 4-(3,4-Dibromothiophenecarbonyl)-2,6,8,12-tetraacetyl-2,4,6,8,10,12-hexaazatetracyclo[5,5,0,0^{3,11},0^{5,9}]dodecane (I). To a solution of chloroanhydride V (9.2 g, 0.03 mol) in dry acetonitrile (60 mL) was added 2,6,8,12-tetraacetyl-2,4,6,8,10,12-hexaazatetracyclo[5,5,0,0^{3,11},0^{5,9}]dodecane (5.04 g, 0.015 mol). The resultant mixture was refluxed for 2 h and then cooled down; the precipitated product was collected by filtration and washed two times with acetonitrile.

The dried creamy-colored sediment was recrystallized from 70% (by vol) aqueous ethanol. The resultant product was washed with water three times and air-dried to furnish 4-(3,4-dibromothiophenecarbonyl)-2,6,8,12-tetraacetyl-2,4,6,8,10,12-hexaazatetracyclo[5,5,0,0^{3,11},0^{5,9}]dodecane as a colorless crystalline product with an assay of 99% (as per HPLC). Yield: 7.19 g (79.4%). mp: 332–334 °C. Calcd for C₁₉H₂₀Br₂N₆O₅S (%): C, 37.76; H, 3.34; Br, 26.45; N, 13.91; O, 13.24; S, 5.31; found (%): C, 37.68; H, 3.24; N, 13.82; S, 5.37. IR (ν /cm⁻¹): 3287, 3119, 3005, 1657, 1504, 1425, 1356, 1323, 1289, 1250, 1162, 1045, 984, 893, 878, 742, 715, 623. ¹H NMR (DMSO-*d*₆, δ ppm): 1.85–2.15 (m, 12H, CH₃CO), 4.75–5.12 (m, 1H, NH), 5.45–5.67 (m, 2H, CH), 5.92–6.85 (m, 4H, CH), 8.08–8.18 (m, 1H, CH). ¹³C NMR (DMSO-*d*₆, δ ppm): 21.16, 21.47, 22.19, 22.43, 22.60, 22.90 (C, CH₃, CH₃CO); 65.07, 67.70, 69.3, 70.31, 71.3, 73.12 (C, CH); 113.13, 114.63 (C, arom.); 127.5 (C, CH, arom.); 132.14 (C, arom.); 162.63, 162.78 (C, CO); 166.7, 167.1, 167.5, 167.9 (C, CO, CH₃CO).

Animals. The experiments were carried out on adult inbred male CBA mice ($n = 24$), outbred male stock CD1 mice ($n = 45$), outbred female stock CD1 mice ($n = 40$), and outbred male stock CD rats ($n = 74$) (1st category conventional animals). The animals were obtained from the Department of Experimental Biomodelling, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine (animal health certificate). Animal maintenance and experimental design were approved by the Bioethics Committee of the E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine (JACUC protocol no. 96092015) and complied with the directive 2010/63/EU of the European Parliament and the Council of the European Union on the protection of animals used for scientific purposes, Order no. 199n of the Ministry of Health of the Russian Federation (August 1, 2016).

Study Design. When the maximum possible single injection volume of thioiwurtzine was used, LD₅₀ (or animal death) was not achieved. The compound was daily administered per os through a probe in a dose range of 50–200 mg/kg (mice) and 25–300 mg/kg (rats) for 1–4 days (Tables 1–3); the last administration was carried out 1 h prior to the pain sensitivity test. The reference drugs were NSAID diclofenac (Hemofarm), administered orally in a dose of 10 mg/kg in a volume of 0.2 mL/mouse and in a dose of 5 mg/kg in a volume of 0.5 mL/rat, NSAID ketorolac (Dr. Reddy's Laboratories Ltd.), administered orally in a dose of 10 mg/kg, and Tramadol (Organic), administered in a dose of 20 mg/kg via a probe in the form of solution in purified water in a volume of 0.2 mL/mouse. The suggested doses of reference drugs matched the average therapeutic doses in humans.⁴² The animals of the negative control group received vehicle (water–Tween mixture) in an equivalent volume via the same route.

Animal Methods. The analgesic activity of thioiwurtzine was assessed in behavioral tests with thermal and chemical exposures and in the Randall–Selitto test with mechanical compression of the normal paw pad and with formalin edema.

Hot Plate Test. The hot plate test is basic in analgesic activity assessment studies; it involves behavioral responses to pain, controlled by cortical and subcortical structures of the brain.⁴³ One hour after compound administration, the test was performed using a Hot Plate Analgesia Meter (Columbus Instruments). The rats were placed on a plate heated at 54.0 ± 0.5 °C, after which pain reaction latency was recorded (licking front and hind paw pads). Analgesic activity was measured by the mean latency in the group and percentage of the pain response inhibition (%PRI), according to the formula $(T_{\text{control}} - T_{\text{experiment}})/T_{\text{control}} \times 100\%$, where T is the pain response latency in the corresponding group.

Acetic Acid Writhing Test. The acetic acid writhing test is aimed at the assessment of acute visceral deep pain.^{42–47} The specific response to pain (writhing) was caused by intraperitoneal injection of 0.75% acetic acid solution in a volume of 0.1 mL/10 g body weight. The analgesic effect was evaluated by the ability of the compound (within 20 min after the injection) to reduce the number of writhings (in %) in comparison with the control group.

Randall–Selitto Test. The Randall–Selitto test (Randall and Selitto, 1957), intended to serve as a tool to assess the effect of analgesic agents on the response thresholds to mechanical pressure stimulation, is usually used by a number of investigators to evaluate inflammatory painful responses.^{42–47} An Ugo Basile electronic device based on the Randall–Selitto principle, which allows testing pain in a quantitative manner by pressuring the hind limbs of animals, has been used. Hyperalgesia was induced by subcutaneous injection of 2% formalin solution in a volume of 50 μ L intraplantarly into the right hind paw pad after 1 h of compound administration. The Randall–Selitto test was performed twice on each individual; 1 and 4 h after compound administration on the left hind paw pad and in the first 1–5 and 40–50 min after inducing hyperalgesia on the right hind paw pad. Analgesic activity was evaluated by the ability of the compound to change the response threshold in comparison with the positive and negative control groups.

The rats were sacrificed by CO₂ inhalation, and the mice were killed by craniocervical dislocation.

Statistical Processing. Statistical processing of the results was performed using ANOVA (Statistica 6.0). For all data, the mean (X) and standard error of the mean (m) were calculated (shown in tables); n is the number of variants in the group. Differences in the studied parameters were assessed with the nonparametric Mann–Whitney U test for testing hypotheses about the homogeneity of the means. The differences were significant at $p < 0.05$.

Homology Modeling. Several structures for the opioid receptors are available in the PDB. However, they usually are not complete, have average resolutions, lack residues, or are crystallized in complex with other proteins. This does not make them great choices for docking studies. In an attempt at consistency, the mu, kappa, delta, and ORL1 opioid receptors were constructed using the corresponding human sequences (respective UniProtKB identifier P35372, P41145, P41143, and P41144) and the online software I-TASSER from the Zhang Lab.³⁹ This iterative modeling software can use several different partial templates when no single valid template is available. Five models for each receptor were computed using the software

default options, and the five best ones were further imported into the MOE software to be checked, charged, and minimized using the Amber 14:ETH force field.

The structure of the TRPA1 human receptor was directly extracted from the PDB file 6PQO. The homology model for the human TRPV1 ion channel was built using the UniProtKB sequence Q8NER1 of the human protein and the rat PDB structure 3J5Q as a template. The model was calculated using the MOE software and the homology modeling module. The PDB file 5IS0 was then used to determine the position of the ligand in the complex.

The homology model for the Ca_v 1.2 calcium channel was built using the UniProtKB sequence Q13936 (isoform 1) of the human voltage-gated calcium channel subunit α_{1C} Ca_v 1.2 and the PDB structure 6JPS of the rabbit Ca_v1.1/ nifedipine complex (resolution 2.90 Å) as a template. The alignment statistics were calculated as follows: 66.4% identity, 75.3% similarity, and 4.7% gaps for a total length of 1359 residues. Prior to the homology modeling, the geometry of all the molecules, bonds, and charges of the PDB structure 6JPS was checked using the structure preparation tool of the MOE software (MOE 2020, Chemical Computing Group, Köln, Germany) and minimized with the Amber 14:EHT forcefield implemented within the MOE software. The homology model was generated using the α_{1C} subunit as the template and the MOE standard parameters in the protein/homology model module. Several loops (215–232, 446–509, 776–892, 941–962, and 1326–1374) were added as the corresponding residues did not exist in the template, but their structure and position were checked and none of them were involved in the interaction with nifedipine.

Docking. The docking procedures were performed with the GOLD³⁸ software (version 2020.3) using the HERMES⁴⁸ interface (CCDC, Cambridge Crystallographic Data Centre) and the implemented GOLD Wizard. We used the GOLD standard parameters for the docking, with the exploration of a spherical site (10 Å radius) centered on the previously cocrystallized ligands. The settings allowed for protein flexibility for the side chains of the residues but not for the backbone of the proteins. The genetic algorithm parameter was set to a number of 200 poses with the activation of the early stop function. We used the Astex scoring potential fitness function⁴⁹ for calculating the docking scores and the Chemscore scoring function^{40,41} for the rescore of the results.

Molecular Dynamics. MD simulations were performed for the model of the mu receptor and the homology model of the Ca_v 1.2 calcium channel in the presence of thioiwurtzine using the Amber 14:EHT force field implemented in the MOE software. A lipid bilayer surrounding the calcium channel composed of 1,2-dioleoyl-*sn*-glycero-3-phosphoethanolamine and 1,2-dioleoyl-*sn*-glycero-3-phospho-rac-1-glycerol with a respective ratio of 3:1 was generated with the MOE lipid generator, using the PACKMOL-Memgen approach.^{50–52} TIP3P water molecules^{53,54} were added, as well as Na⁺ and Cl⁻ ions in order to simulate a 0.1 M ionic force, and the pH was set at 7.4. Standard Amber 14:EHT parameters were used for MD. A quick minimization was performed prior to the start of the MD simulations. The geometry of all the molecules, bonds, and charges was then checked using the structure preparation tool in MOE, in order to start the molecular simulations. After a preliminary equilibration phase, 200 ns molecular simulations were performed. A frame was saved every 200 ps, leading to a total of 1000 frames.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acsomega.1c01786>.

¹H and ¹³C NMR spectra for compounds I, IV, VIII, and IX, IR spectra for I, RMSD plots for the MD calculations, and structural PDB data for the different models of the receptors (mu, kappa, delta, ORL1, and Ca_v 1.2) (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

Daria A. Kulagina – *Institute for Problems of Chemical and Energetic Technologies, Siberian Branch of the Russian Academy of Sciences (IPCET SB RAS), Biysk 659322, Altai Krai, Russia; Email: imbiri@rambler.ru*

Raphael Terreux – *Équipe ECMO, Laboratoire de Biologie Tissulaire et d'Ingénierie (LBTI), UMR5305, Université Lyon 1, Lyon 69367, France; orcid.org/0000-0003-1243-7413; Email: raphael.terreux@univ-lyon1.fr*

Authors

Stephanie Aguero – *Équipe ECMO, Laboratoire de Biologie Tissulaire et d'Ingénierie (LBTI), UMR5305, Université Lyon 1, Lyon 69367, France*

Simon Megy – *Équipe ECMO, Laboratoire de Biologie Tissulaire et d'Ingénierie (LBTI), UMR5305, Université Lyon 1, Lyon 69367, France*

Valeria V. Eremina – *Institute for Problems of Chemical and Energetic Technologies, Siberian Branch of the Russian Academy of Sciences (IPCET SB RAS), Biysk 659322, Altai Krai, Russia*

Alexander I. Kalashnikov – *Institute for Problems of Chemical and Energetic Technologies, Siberian Branch of the Russian Academy of Sciences (IPCET SB RAS), Biysk 659322, Altai Krai, Russia*

Svetlana G. Krylova – *Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk 634028, Russia*

Ksenia A. Lopatina – *Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk 634028, Russia*

Mailys Fournier – *Équipe ECMO, Laboratoire de Biologie Tissulaire et d'Ingénierie (LBTI), UMR5305, Université Lyon 1, Lyon 69367, France*

Tatyana N. Povetyeva – *Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk 634028, Russia*

Alexander B. Vorozhtsov – *National Research Tomsk State University, Tomsk 634050, Russia*

Sergey V. Sysolyatin – *Institute for Problems of Chemical and Energetic Technologies, Siberian Branch of the Russian Academy of Sciences (IPCET SB RAS), Biysk 659322, Altai Krai, Russia*

Vadim V. Zhdanov – *Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk 634028, Russia*

Complete contact information is available at:

<https://pubs.acs.org/doi/10.1021/acsomega.1c01786>

Author Contributions

[†]S.A. and S.M. contributed equally to this work as first coauthors. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The authors would like to thank Johnny Truong for his work on the homology model of the Ca_v 1.2 calcium channel and the subsequent docking of thioiwurtzine.

ABBREVIATIONS

GOLD software	Genetic Optimization for Ligand Docking software
MD	molecular dynamics
MOE software	Molecular Operating Environment software
NSAIDs	Nonsteroidal anti-inflammatory drugs
ORL1	opioidlike receptor 1
vs	versus
TRP	transient receptor potential

REFERENCES

- (1) Varrassi, G. Severe Chronic Pain – the Reality of Treatment in Europe. *Curr. Med. Res. Opin.* **2011**, *27*, 2063–2064.
- (2) Piper, B. J.; Shah, D. T.; Simoyan, O. M.; McCall, K. L.; Nichols, S. D. Trends in Medical Use of Opioids in the U.S., 2006–2016. *Am. J. Prev. Med.* **2018**, *54*, 652–660.
- (3) Cawich, S. O.; Deonaraine, U.; Harding, H. E.; Dan, D.; Naraynsingh, V. Chapter 46—Cannabis and Postoperative Analgesia. In *Handbook of Cannabis and Related Pathologies*; Preedy, V. R., Ed.; Academic Press: San Diego, 2017; pp 450–458.
- (4) Karateev, A. E.; Nasonov, E. L.; Yakhno, N. N.; Ivashkin, V. T.; Chichasova, N. V.; Alekseeva, L. I.; Karpov, Y. A.; Evseev, M. A.; Kukushkin, M. L.; Danilov, A. B.; Vorobyeva, O. V.; Amelin, A. V.; Novikova, D. S.; Drapkina, O. M.; Kopenkin, S. S.; Abuzarova, G. R. Clinical guidelines “Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice”. *Mod. Rheumatol. J.* **2015**, *9*, 4–23.
- (5) Argoff, C. E.; Albrecht, P.; Irving, G.; Rice, F. Multimodal Analgesia for Chronic Pain: Rationale and Future Directions. *Pain Med.* **2009**, *10*, S53–S66.
- (6) Pogodin, P. V.; Lagunin, A. A.; Filimonov, D. A.; Nicklaus, M. C.; Poroikov, V. V. Improving (Q)SAR Predictions by Examining Bias in the Selection of Compounds for Experimental Testing. *SAR QSAR Environ. Res.* **2019**, *30*, 759–773.
- (7) Macarron, R.; Banks, M. N.; Bojanic, D.; Burns, D. J.; Cirovic, D. A.; Garyantes, T.; Green, D. V. S.; Hertzberg, R. P.; Janzen, W. P.; Paslay, J. W.; Schopfer, U.; Sittampalam, G. S. Impact of High-Throughput Screening in Biomedical Research. *Nat. Rev. Drug Discovery* **2011**, *10*, 188–195.
- (8) Singh, N.; Chapat, L.; Villoutreix, B. O. Virtual Screening Web Servers: Designing Chemical Probes and Drug Candidates in the Cyberspace. *Briefings Bioinf.* **2020**, *22*, 1790.
- (9) Krylova, S. G.; Amosova, E. N.; Zueva, E. P.; Razina, T. G.; Rybalkina, O. Y.; Lopatina, K. A.; Sysolyatin, S. V.; Kalashnikov, A. I.; Malykhin, V.; Dygai, A. M.; Zhdanov, V. V.; Vorozhtsov, A. B.; Zhukov, A. S. 4-(3,4-Dibromothiophene Carbonyl)-2,6,8,12-Tetraacetyl-2,4,6,8,10,12-Hexaazatetracyclo[5,5,0,0,3,11,05,9]Dodecane as Analgesic Agent and Method for Production Thereof. RU 2565766 C1, October 20, 2015.
- (10) Solovev, V. N. Effect of nitroglycerin and menthol on vascular dilatation. *Klin. Med.* **1949**, *27*, 57–62.
- (11) Lepow, H.; Turner, R. A. Peripheral Vasodilatation in Response to Controlled-Release Nitroglycerin. *Southwest. Med.* **1966**, *47*, 190–192.
- (12) Durlach, J.; Lemerre, L.; Lepage, F. Treatment of premenstrual syndrome & pelvic pain syndrome with sugar-coated enteric tablets of potassium nitrate. *Rev. Fr. Gynecol. Obstet.* **1958**, *53*, 17–24.
- (13) Collins, J. F.; Gingold, J.; Stanley, H.; Simring, M. Reducing Dental Hypersensitivity with Strontium Chloride and Potassium Nitrate. *Gen. Dent.* **1984**, *32*, 40–43.
- (14) Nair, U. R.; Sivabalan, R.; Gore, G. M.; Geetha, M.; Asthana, S. N.; Singh, H. Hexanitrohexaazaisowurtzitan (CL-20) and CL-20-Based Formulations (Review). *Combust., Explos. Shock Waves* **2005**, *41*, 121–132.
- (15) Tolstikova, T. G.; Morozova, E. A.; Sysolyatin, S. V.; Kalashnikov, A. I.; Zhukova, Y. I.; Surmachev, V. N. Synthesis and Biological Activity of the Derivatives of 2,4,6,8,10,12-Hexaazatetracyclo[5.5.0.0.3,11.05,9]Dodecane. *Chem. Sustainable Dev.* **2010**, *4*, 431–436.
- (16) Sysolyatin, S. V.; Lobanova, A. A.; Chernikova, Y. T.; Sakovich, G. V. Methods of Synthesis and Properties of Hexanitrohexaazaisowurtzitan. *Russ. Chem. Rev.* **2005**, *74*, 757.
- (17) Menke, K. Organic Chemistry of Explosives, J. P. Agrawal, R. D. Hodgson. *Pyrotechnics* **2007**, *32*, 182.
- (18) Krylova, S. G.; Povet’eva, T. N.; Zueva, E. P.; Suslov, N. I.; Amosova, E. N.; Razina, T. G.; Lopatina, K. A.; Rybalkina, O. Y.; Nesterova, Y. V.; Afanas’eva, O. G.; Kiseleva, E. A.; Sysolyatin, S. V.; Kulagina, D. A.; Zhdanov, V. V. Analgesic Activity of Hexaazaisowurtzitan Derivatives. *Bull. Exp. Biol. Med.* **2019**, *166*, 461–465.
- (19) Lin, G.; Tsai, H.-J.; Tsai, Y.-H. Cage Amines as the Stopper Inhibitors of Cholinesterases. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 2887–2890.
- (20) Krylova, S. G.; Povetyeva, T. N.; Sysolyatin, S. V.; Suslov, N. I.; Zueva, E. P.; Nesterova, Y. V.; Afanasyeva, O. G.; Lopatina, K. A.; Kulpin, P. V.; Zhdanov, V. V.; Kulagina, D. A.; Malykhin, V. V.; Vorozhtsov, A. B. 4-(3,4-Dibromothiophene Carbonyl)-2,6,8,12-Tetraacetyl-2,4,6,8,10,12-Hexaazatetracyclo[5,5,0,0,3,11,05,9]-Dodecane Used as an Anticonvulsant. Patent RU 2684107 C1 Russian Federation, IPC C07D, A61K, A61P, January 12, 2018.
- (21) Sample Size Software|Power Analysis Software|PASS|NCSS.com. <https://www.ncss.com/software/pass/> (accessed Feb 19, 2021).
- (22) Bellamy, A. J. Reductive Debenzylation of Hexabenzylhexaazaisowurtzitan. *Tetrahedron* **1995**, *51*, 4711–4722.
- (23) Kalashnikov, A. I.; Sysolyatin, S. V.; Sakovich, G. V.; Surmachev, I. A.; Surmachev, V. N.; Lapina, Y. T. Debenzylation of 2,6,8,12-Tetraacetyl-4,10-Dibenzyl-2,4,6,8,10,12-Hexaazatetracyclo[5.5.0.0.3,11.05,9]Dodecane. *Russ. Chem. Bull.* **2009**, *58*, 2164–2168.
- (24) Ananikov, V. P.; Khemchyan, L. L.; Ivanova, Y. V.; Bukhtiyarov, V. I.; Sorokin, A. M.; Prosvirin, I. P.; Vatsadze, S. Z.; Medved’ko, A. V.; Nuriev, V. N.; Dilman, A. D.; Levin, V. V.; Koptuyg, I. V.; Kovtunov, K. V.; Zhivonitko, V. V.; Likholobov, V. A.; Romanenko, A. V.; Simonov, P. A.; Nenajdenko, V. G.; Shmatova, O. I.; Muzalevskiy, V. M.; Nechaev, M. S.; Asachenko, A. F.; Morozov, O. S.; Dzhevakov, P. B.; Osipov, S. N.; Vorobyeva, D. V.; Topchiy, M. A.; Zotova, M. A.; Ponomarenko, S. A.; Borshchev, O. V.; Luponosov, Y. N.; Rempel, A. A.; Valeeva, A. A.; Stakheev, A. Y.; Turova, O. V.; Mashkovsky, I. S.; Sysolyatin, S. V.; Malykhin, V. V.; Bukhtiyarova, G. A.; Terent’ev, A. O.; Krylov, I. B. Development of New Methods in Modern Selective Organic Synthesis: Preparation of Functionalized Molecules with Atomic Precision. *Russ. Chem. Rev.* **2014**, *83*, 885–985.
- (25) Lewanowitsch, T.; Irvine, R. J. Naloxone and its quaternary derivative, naloxone methiodide, have differing affinities for μ , δ , and κ opioid receptors in mouse brain homogenates. *Brain Res.* **2003**, *964*, 302–305.
- (26) Wishart, D. S.; Feunang, Y. D.; Guo, A. C.; Lo, E. J.; Marcu, A.; Grant, J. R.; Sajed, T.; Johnson, D.; Li, C.; Sayeeda, Z.; Assempour, N.; Iynkkaran, I.; Liu, Y.; Maciejewski, A.; Gale, N.; Wilson, A.; Chin, L.; Cummings, R.; Le, D.; Pon, A.; Knox, C.; Wilson, M. DrugBank 5.0: A

Major Update to the DrugBank Database for 2018. *Nucleic Acids Res.* **2018**, *46*, D1074–D1082.

(27) Zamponi, G. W.; Striessnig, J.; Koschak, A.; Dolphin, A. C. The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. *Pharmacol. Rev.* **2015**, *67*, 821–870.

(28) Gou, X.; Yu, X.; Bai, D.; Tan, B.; Cao, P.; Qian, M.; Zheng, X.; Chen, L.; Shi, Z.; Li, Y.; Ye, F.; Liang, Y.; Ni, J. Pharmacology and Mechanism of Action of HSK16149, a Selective Ligand of $\alpha\delta$ Subunit of Voltage-Gated Calcium Channel with Analgesic Activity in Animal Models of Chronic Pain. *J. Pharmacol. Exp. Ther.* **2020**, *376*, 330.

(29) Bourinet, E.; Zamponi, G. W. Voltage Gated Calcium Channels as Targets for Analgesics. *Curr. Top. Med. Chem.* **2005**, *5*, 539–546.

(30) Weiss, N.; Waard, M. D. Les canaux calciques dépendants du voltage au cœur de la douleur. *Med./Sci.* **2006**, *22*, 396.

(31) Todorovic, S. M.; Meyenburg, A.; Jevtovic-Todorovic, V. Mechanical and Thermal Antinociception in Rats Following Systemic Administration of Mibefradil, a T-Type Calcium Channel Blocker. *Brain Res.* **2002**, *951*, 336–340.

(32) Todorovic, S. M.; Pathirathna, S.; Meyenburg, A.; Jevtovic-Todorovic, V. Mechanical and Thermal Anti-Nociception in Rats after Systemic Administration of Verapamil. *Neurosci. Lett.* **2004**, *360*, 57–60.

(33) Feliks, K. B.; Wrońska, D. Voltage-Gated Calcium Channel Antagonists: Potential Analgesics for Jejunal Pains. *Pain Relief—From Analgesics to Alternative Therapies*; IntechOpen, 2017.

(34) Ray, B.; Kumar, R.; Mehra, R. L-Type Calcium Channel Blockers, Morphine and Pain: Newer Insights. *Indian J. Anaesth.* **2010**, *54*, 127–131.

(35) Prado, W. A. Involvement of Calcium in Pain and Antinociception. *Braz. J. Med. Biol. Res.* **2001**, *34*, 449–461.

(36) Del Pozo, E.; Caro, G.; Baeyens, J.M. Analgesic Effects of Several Calcium Channel Blockers in Mice. *Eur. J. Pharmacol.* **1987**, *137*, 155–160.

(37) Ray, S. B.; Mishra, P.; Verma, D.; Gupta, A.; Wadhwa, S. Nimodipine Is More Effective than Nifedipine in Attenuating Morphine Tolerance on Chronic Co-Administration in the Rat Tail-Flick Test. *Indian J. Exp. Biol.* **2008**, *46*, 219–228.

(38) GOLD—Protein Ligand Docking Software—The Cambridge Crystallographic Data Centre (CCDC). <https://www.ccdc.cam.ac.uk/solutions/csd-discovery/Components/Gold/> (accessed Feb 9, 2021).

(39) I-TASSER server for protein structure and function prediction. <https://zhanglab.cmb.med.umich.edu/I-TASSER/> (accessed Feb 16, 2021).

(40) Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P. Empirical Scoring Functions: I. The Development of a Fast Empirical Scoring Function to Estimate the Binding Affinity of Ligands in Receptor Complexes. *J. Comput.-Aided Mol. Des.* **1997**, *11*, 425–445.

(41) Baxter, C. A.; Murray, C. W.; Clark, D. E.; Westhead, D. R.; Eldridge, M. D. Flexible Docking Using Tabu Search and an Empirical Estimate of Binding Affinity. *Proteins* **1998**, *33*, 367–382.

(42) *Manual for Preclinical Studies of New Pharmacological Substances. Part I*; Mironov, A. N., Ed.; Moscow, 2013 (in Russian).

(43) Rice, A. S. C.; Cimino-Brown, D.; Eisenach, J. C.; Kontinen, V. K.; Lacroix-Fralish, M. L.; Machin, I.; Mogil, J. S.; Stöhr, T.; Preclinical Pain Consortium. Animal Models and the Prediction of Efficacy in Clinical Trials of Analgesic Drugs: A Critical Appraisal and Call for Uniform Reporting Standards. *Pain* **2008**, *139*, 243–247.

(44) Woolfe, G.; Macdonald, A. D. The Evaluation of the Analgesic Action of Pethidine Hydrochloride (Demerol). *J. Pharmacol. Exp. Ther.* **1944**, *80*, 300–307.

(45) Koster, R.; Anderson, M.; De Beer, E. Acetic Acid-Induced Analgesic Screening. *Fed. Proc.* **1959**, *18*, 412.

(46) Randall, L. O.; Selitto, J. J. A Method for Measurement of Analgesic Activity on Inflamed Tissue. *Arch. Int. Pharmacodyn. Ther.* **1957**, *111*, 409–419.

(47) Barrot, M. Tests and Models of Nociception and Pain in Rodents. *Neuroscience* **2012**, *211*, 39–50.

(48) Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and Validation of a Genetic Algorithm for Flexible Docking. *J. Mol. Biol.* **1997**, *267*, 727–748.

(49) Mooij, W. T. M.; Verdonk, M. L. General and Targeted Statistical Potentials for Protein-Ligand Interactions. *Proteins* **2005**, *61*, 272–287.

(50) Martínez, J. M.; Martínez, L. Packing Optimization for Automated Generation of Complex System's Initial Configurations for Molecular Dynamics and Docking. *J. Comput. Chem.* **2003**, *24*, 819–825.

(51) Martínez, L.; Andrade, R.; Birgin, E. G.; Martínez, J. M. PACKMOL: A Package for Building Initial Configurations for Molecular Dynamics Simulations. *J. Comput. Chem.* **2009**, *30*, 2157–2164.

(52) Schott-Verdugo, S.; Gohlke, H. PACKMOL-Memgen: A Simple-To-Use, Generalized Workflow for Membrane-Protein-Lipid-Bilayer System Building. *J. Chem. Inf. Model.* **2019**, *59*, 2522–2528.

(53) Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of Simple Potential Functions for Simulating Liquid Water. *J. Chem. Phys.* **1983**, *79*, 926–935.

(54) Neria, E.; Fischer, S.; Karplus, M. Simulation of Activation Free Energies in Molecular Systems. *J. Chem. Phys.* **1996**, *105*, 1902–1921.